New and Improved Service

Posted:
26
August 2004

Claire Tucker, Head of Sales and Marketing

Richmond Pharmacology's (RPL's) highly successful business team has recently undergone a re-organisation to enhance the outstanding service we provide to our valued clients.Claire Tucker, Head of Sales and Marketing, commented:‘Our improved structure includes dedicated business Account Managers, specifically allocated to a particular client and able to guide them through the initial stages of introduction and study specific contract negotiation. These Account Managers continue to be at hand throughout as an additional point of contact until the study has reached its completion. As usual, our proficient Clinical Project Managers will co-ordinate the smooth day-to-day running of the study and will continue to work on a one to one basis with client teams. I am delighted with the new structure and the impact this is already having on our clients.’This framework has been introduced to ensure even better communication from initial contact through to close out, maintaining RPL's supportive and personal approach.Providing additional support for Phase II is our dedicated Phase II Department, see more on our patient studies page.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more